About
About START

Welcome to the START Center for Cancer Research. We are a global leader in cancer research, dedicated to the relentless pursuit of hope for patients and their families.

About

Company

Hope Hub

Leadership

Principal Investigators

Careers

Contact

Our Services

Preclinical

Early Phase
Who We Serve
Who We Serve

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment.

Visit The START Hope Hub

We believe that every patient should have the opportunity to access clinical trials, regardless of where they receive their cancer treatment. Designed to help you understand, explore, and enroll in early-phase oncology trials, the START Hope Hub will help guide you through the clinical trial process with confidence.

Explore Hope Hub

Patients & Family

Patients

Explore Clinical Trials

About Clinical Trials

Patient Stories

Patient Advocacy Groups

Referring Physicians

Referring Physicians

Hospitals & Oncology Practices

Hospitals & Oncology Practices

Pharma

Pharma
START Locations
START Research Centers

100,000+ square feet of world-class research facilities

United States Locations

START - San Antonio

START - Midwest

START - Mountain Region

START - Carolinas

START - Dallas Fort Worth

START - New Jersey

START - New York-Long Island

START - Los Angeles

Europe Locations

START - Madrid - CIOCC

START - Madrid - FJD

START - Barcelona

START - Rioja

START - Pediatrics

START - Lisbon

START - Dublin
Resources
Resources

Stay up to date with everything at START, from blog insights and press and newsroom updates to expert-led webinars and much more.

Resources

Blog

Events

Newsroom

Press

Publications

Webinars

Featured Resources

Newsroom

START Partners with Trialing to Expand Access to Oncology Clinical Trials Across Europe

Newsroom

START Appoints Dr. Frank Smith President of its XenoSTART Preclinical Research Business Unit
Hope Hub
Find a Trial

Press

MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor

MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor Read More »

Why Moving More Cancer Trials Into the Community Benefits Patients and Sponsors

Leave a Comment / Press / Joel E

Why Moving More Cancer Trials Into the Community Benefits Patients and Sponsors Read More »

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer

Leave a Comment / Press / Joel E

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer Read More »

Enabling Successful Sites Ep. 3: Taking the Complexity Out of Oncology Trials

Leave a Comment / Press / Joel E

Enabling Successful Sites Ep. 3: Taking the Complexity Out of Oncology Trials Read More »

Finding Hope with Clinical Trials: Q&A with Nick Slack

Leave a Comment / Press / Joel E

Finding Hope with Clinical Trials: Q&A with Nick Slack Read More »

The Undruggable Cancer Target: KRAS Inhibitors Move Ahead in the Clinic

Leave a Comment / Press / Joel E

The Undruggable Cancer Target: KRAS Inhibitors Move Ahead in the Clinic Read More »

CEO of START Reinforces the Importance of the Santa Maria Phase 1 Oncology Trial Center

Leave a Comment / Press / Joel E

CEO of START Reinforces the Importance of the Santa Maria Phase 1 Oncology Trial Center Read More »

The Connection Between Young Adults and Colon Cancer

Leave a Comment / Press / Joel E

The Connection Between Young Adults and Colon Cancer Read More »

Early Exposure & Site Network Support Enable PI’s Enduring Interest in Research

Leave a Comment / Press / Joel E

Early Exposure & Site Network Support Enable PI’s Enduring Interest in Research Read More »

First Patient Dosed with NILK-2301 in Phase I Clinical Trial

Leave a Comment / Press / Joel E

First Patient Dosed with NILK-2301 in Phase I Clinical Trial Read More »

← Previous 1 … 4 5 6 Next →

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.

Who We Serve

Patients
Pharma
Hospitals & Oncology Practices

Services

Preclinical
Early Phase

About

Company
Leadership
Principal Investigators
Careers
Contact

Resources

Blog
Events
Newsroom
Patient Stories
Press
Publications
Webinars

START Locations

START - San Antonio
START - Midwest
START - Mountain Region
START - Carolinas
START - Dallas Fort Worth
START - New Jersey
START - New York-Long Island
START - Los Angeles
START - Madrid - CIOCC
START - Madrid - FJD
START - Barcelona
START - Rioja
START - Pediatrics
START - Lisbon
START - Dublin

Patients & Family

Explore Clinical Trials
About Clinical Trials
Patient Stories

Referring Physicians

Find a Trial

Facebook Linkedin X-twitter

Privacy Policy
Cookie Policy
Site Map

About START

About

Our Services

Who We Serve

Visit The START Hope Hub

Patients & Family

Referring Physicians

Hospitals & Oncology Practices

Pharma

Resources

Resources

Featured Resources

START Partners with Trialing to Expand Access to Oncology Clinical Trials Across Europe

START Appoints Dr. Frank Smith President of its XenoSTART Preclinical Research Business Unit

Press

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.